

Thermo Fisher invests \$44M in bioprocessing manufacturing site in Utah, US

21 April 2022 | News

The site has hired more than 300 employees and has the potential to employ up to 450 people



Thermo Fisher Scientific has opened its new single-use technology manufacturing site in Ogden, Utah in the US. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies.

The \$44 million facility is part of Thermo Fisher's \$650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19.

The Ogden site is a 55,000-square-foot facility that will manufacture highly customizable bioprocess container (BPC) systems. These BPCs are used for the delivery, processing, separation, storage and transportation of critical liquids and readily integrate into systems across all steps in the production of life-saving biologics, vaccines and cell and gene therapies.

The Ogden site has hired more than 300 employees and has the potential to employ up to 450 people across safety, quality, manufacturing, HR, engineering and warehousing. Thermo Fisher currently employs more than 2,000 colleagues across the state of Utah, establishing a critical hub for bioprocessing.